<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The purpose of this study was to explore the relationship between <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality </plain></SENT>
<SENT sid="1" pm="."><plain>We were interested to determine if data from major randomised controlled trials would support a hypothesis that improving glycaemic control may reduce the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> outcomes </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We included major randomised controlled trials conducted with an overall aim of intensified glycaemic control in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We abstracted data from published papers and supplemental material and conducted separate meta-analyses of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Four trials reported <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality for the intensive (222 events in 53,892 person-years) and standard control (155 events in 38,743 person-years) arms (UK Prospective <z:mp ids='MP_0002055'>Diabetes</z:mp> Study [UKPDS] 33, UKPDS 34, Action to Control Cardiovascular Risk in <z:mp ids='MP_0002055'>Diabetes</z:mp> [ACCORD] and Veterans Affairs <z:mp ids='MP_0002055'>Diabetes</z:mp> Trial [VADT]); the summary risk ratio for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality was 1.00 (95% CI 0.81-1.24; I² = 0%) </plain></SENT>
<SENT sid="5" pm="."><plain>Excluding the UKPDS <z:chebi fb="0" ids="6801">metformin</z:chebi> trial resulted in a pooled risk estimate of 1.03 (95% CI 0.83-1.29; I² = 0%) </plain></SENT>
<SENT sid="6" pm="."><plain>Three trials reported <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence for the study arms (Action in <z:mp ids='MP_0002055'>Diabetes</z:mp> and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">Vascular Disease</z:e>: Preterax and Diamicron <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> Controlled Evaluation [ADVANCE], PROspective pioglitAzone Clinical Trial In macroVascular Events [PROactive], <z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> Evaluated for Cardiac Outcomes and Regulation of Glycaemia in <z:mp ids='MP_0002055'>Diabetes</z:mp> [RECORD]) with 357 events in 47,974 person-years with improved glycaemic control and 380 events in 45,009 person-years in the control arms; the pooled risk ratio for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence was 0.91 (95% CI 0.79-1.05; I² = 0%) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: Data from large randomised controlled trials of intensified glycaemic control suggest that <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk is not reduced by improving glycaemic control in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>These data therefore do not support the hypothesis that <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> is causally linked to increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
</text></document>